Shah, N. C., Ngwube, A., Suresh, T., Sowa, A., Abraham, A., Anderson, E., Andreansky, M., Bhatia, M., Chaudhury, S., Cuvelier, G. D. E., Dalal, J., Grimley, M., Jacobsohn, D., Kamani, N., Krajewski, J., Krishnamurti, L., Saini, S., Skiles, J., & Shenoy, S. (2025). Impact of Abatacept Inclusive Graft Versus Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy. Transplantation and Cellular Therapy. https://doi.org/10.1016/j.jtct.2025.06.015

Wufsus, A., Delicou, S., El Rassi, F., Andemariam, B., Abboud, M. R., Kanter, J., Telen, M. J., Githanga, J., Inati, A., Idris, I. M., Navani, S., Wu, E., & Eisenberger, A. (2025). Etavopivat Reduces Incidence of Vaso-occlusive Crises in Patients With Sickle Cell Disease: Hibiscus Trial Phase 2 Results through 52 Weeks. Journal of Sickle Cell Disease, 2(Supplement_1). https://doi.org/10.1093/jscdis/yoaf013.002

Mishkin, A. D. (2025). Screening Adolescents for Depression in Sickle Cell Disease: It All Starts with Getting the Patients Into Your Office. Pediatric Blood & Cancer. Portico. https://doi.org/10.1002/pbc.31688

Naggayi, S. K., Kalibbala, D., Mboizi, V., Ssenkusu, J. M., Jin, Z., Rosano, C., Munube, D., Wambaka, B., Namazzi, R., Kasirye, P. G., Kabatabaazi, M., Nambatya, G., Murungi, S., Nabaggala, C., Nakafeero, M. R., Troidl, I. R., Opoka, R. O., Idro, R., Bangirana, P., & Green, N. S. (2025). Neurocognitive Gains Among Ugandan Children with Sickle Cell Anemia on Hydroxyurea: 18-month trial interim results. Blood Advances. https://doi.org/10.1182/bloodadvances.2024015073

Mboizi, V., Nabaggala, C., Munube, D., Ssenkusu, J. M., Kasirye, P., Kamya, S., Kawooya, M. G., Boehme, A., Minja, F., Mupere, E., Opoka, R., Rosano, C., Idro, R., & Green, N. S. (2024). Hydroxyurea therapy for neurological and cognitive protection in pediatric sickle cell anemia in Uganda (BRAIN SAFE II): Protocol for a single-arm open label trial. Contemporary Clinical Trials Communications, 42, 101404. https://doi.org/10.1016/j.conctc.2024.101404

Reisz, J. A., Earley, E. J., Nemkov, T., Key, A., Stephenson, D., Keele, G. R., Dzieciatkowska, M., Spitalnik, S. L., Hod, E. A., Kleinman, S., Roubinian, N. H., Gladwin, M. T., Hansen, K. C., Norris, P. J., Busch, M. P., Zimring, J. C., Churchill, G. A., Page, G. P., & D’Alessandro, A. (2024). Arginine metabolism is a biomarker of red blood cell and human aging. Aging Cell. Portico. https://doi.org/10.1111/acel.14388

Akpan, I. J., Bogyo, K., Leeman-Neill, R. J., Wattacheril, J., & Francis, R. O. (2024). Congenital dyserythropoietic anemia type II and ineffective erythropoiesis: challenges in diagnosis and management. Frontiers in Hematology, 3. https://doi.org/10.3389/frhem.2024.1389820

Manzoni, E., Carli, S., Gaignard, P., Schlieben, L. D., Hirano, M., Ronchi, D., Gonzales, E., Shimura, M., Murayama, K., Okazaki, Y., Barić, I., Petkovic Ramadza, D., Karall, D., Mayr, J., Martinelli, D., La Morgia, C., Primiano, G., Santer, R., Servidei, S., … Garone, C. (2024). Deoxyguanosine kinase deficiency: natural history and liver transplant outcome. Brain Communications, 6(3). https://doi.org/10.1093/braincomms/fcae160

Bangirana, P., Boehme, A. K., Birabwa, A., Opoka, R. O., Munube, D., Mupere, E., Kasirye, P., Muwanguzi, G., Musiimenta, M., Ru, G., Green, N. S., & Idro, R. (2024). Neurocognitive impairment in Ugandan children with sickle cell anemia compared to sibling controls: a cross-sectional study. Frontiers in Stroke, 3. https://doi.org/10.3389/fstro.2024.1372949

Verweij, E., Tura, A. K., Gure, T., Pyuza, J., Mchome, B., Kawaza, K., Moons, P., de Winter, D., van’t Oever, R., Spitalnik, S., van der Schoot, C. E., & van den Akker, T. (2024). Monoclonal RhD prophylaxis: high time to evaluate efficacy. The Lancet, 403(10429), 806–807. https://doi.org/10.1016/s0140-6736(23)01888-3

Kanter, J., Thompson, A. A., Kwiatkowski, J. L., Parikh, S., Mapara, M., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Gupta, A. O., Zhang, L., Sheldon-Waniga, E., Gallagher, M., Gruppioni, K., Chawla, A., Elliot, H., Pierciey, F. J., Walters, M. C., & Tisdale, J. F. (2023). Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up. Blood, 142(Supplement 1), 1051–1051. https://doi.org/10.1182/blood-2023-174229

Proli, A., Sawas, A., Ho, G., Wang, J., & Fullerton, C. (2023). Methods for Identification of Blood Product Transfusions in a Cohort of Myelofibrosis Patients: An Assessment of Data Capture Using Insurance Claims and Electronic Health Record Abstraction. Blood, 142(Supplement 1), 7292–7292. https://doi.org/10.1182/blood-2023-189374

Naggayi, S. K., Kalibala, D., Opoka, R., Rosano, C., Munube, D., Kasirye, P., Mupere, E., Mboizi, V., Ssenkusu, J., Green, N. S., Idro, R., & Bangirana, P. (2023). Neurocognitive Improvement with Hydroxyurea Therapy in Children with Sickle Cell Anemia in Uganda: Interim Analysis at Month 18. Blood, 142(Supplement 1), 275–275. https://doi.org/10.1182/blood-2023-190687

Hanna, R., Frangoul, H., McKinney, C., Pineiro, L., Mapara, M., Dalal, J., Chang, K.-H., Jaskolka, M., Kim, K., Farrington, D. L., Wally, M., Mei, B., Lawal, A., Afonja, O. O., & Walters, M. C. (2023). AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia. Blood, 142(Supplement 1), 4996–4996. https://doi.org/10.1182/blood-2023-187397

Kalibala, D., Nabaggala, C., Turyagyenda, L., Mboizi, V., Naggayi, S. K., Kabatabaazi, M., Rosano, C., Munube, D., Kasirye, P., Ssenkusu, J., Opoka, R., Bangirana, P., Green, N. S., Idro, R., & Mupere, E. (2023). Effect of Hydroxyurea Treatment on Body Composition in Children with Sickle Cell Anemia in Uganda Using Bioelectrical Impedance Analysis (BIA). Blood, 142(Supplement 1), 1136–1136. https://doi.org/10.1182/blood-2023-190181

Namazzi, R., Idro, R., Kalibala, D., Ssenkusu, J., Akun, P., Mboizi, V., Gondwe, T. N., Munube, D., Kasirye, P., Nabaggala, C., John, C. C., Green, N. S., Robberstat, B., Hensbroek, B. van, Kuile, F. ter, Phiri, K. S., & Opoka, R. (2023). Malaria in Children with Sickle Cell Anaemia in Areas with Low, Moderate and High Transmission in Uganda. Blood, 142(Supplement 1), 5327–5327. https://doi.org/10.1182/blood-2023-189066

Green, N. S., Manwani, D., Aygun, B., Appiah-Kubi, A., Smith-Whitley, K., Jia, H., & Smaldone, A. (2023). Habit Efficacy Trial: A Multi-Site Randomized Controlled Trial of Community Health Worker Support to Increase Hydroxyurea Adherence of Youth with Sickle Cell Disease. Blood, 142(Supplement 1), 3901–3901. https://doi.org/10.1182/blood-2023-190031

Green, N. S., Rosano, C., Bangirana, P., Opoka, R., Munube, D., Kasirye, P., Kawooya, M., Lubowa, S. K., Mupere, E., Conroy, A., Minja, F. J., Boehme, A. K., Kang, M. S., Honig, L. S., & Idro, R. (2023). Neurofilament light chain: A potential biomarker for cerebrovascular disease in children with sickle cell anaemia. British Journal of Haematology, 203(3), 460–467. Portico. https://doi.org/10.1111/bjh.19036

Carvalho Poyraz, F., Ghoshal, S., Agarwal, S., Park, S., Claassen, J., Hod, E., & Roh, D. (2023). P‐PB‐5 | Anemia Development During Intracerebral Hemorrhage Hospitalization is Associated with Poor Long‐Term Outcomes. Transfusion, 63(S5). Portico. https://doi.org/10.1111/trf.293_17554

Coughlan, A., Klijn, S. L., Xiao, H., White, B., Litkiewicz, M., Kadambi, A., Sichevaya, A., Hnoosh, A., Miteva, D., & Yucel, A. (2023). POSTER: MDS-008 Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS). Clinical Lymphoma Myeloma and Leukemia, 23, S180. https://doi.org/10.1016/s2152-2650(23)00575-x

Hanna, R., Frangoul, H., Mckinney, C., Pineiro, L., Mapara, M., Chang, K.-H., Jaskolka, M., Kim, K., Rizk, M., Afonja, O., Lawal, A., & Walters, M. (2023). S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME. HemaSphere, 7(S3), e05170e0. https://doi.org/10.1097/01.hs9.0000967968.05170.e0

Locatelli, F., Lang, P., Corbacioglu, S., LI, A., De La Fuente, J., Wall, D., Meisel, R., Shah, A. J., Liem, R., Mapara, M., Carpenter, B., Kwiatkowski, J., Domenica Cappellini, M., Kattamis, A., Sheth, S., Grupp, S., Kohli, P., Shi, D., Ross, L., … Frangoul, H. (2023). S270: TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA. HemaSphere, 7(S3), e8473180. https://doi.org/10.1097/01.hs9.0000967992.84731.80

Kudose, S., Cossey, L. N., Canetta, P. A., Sekulic, M., Vanbeek, C. A., Huls, F. B., Gupta, I., Bu, L., Alexander, M. P., Cornell, L. D., Fidler, M. E., Markowitz, G. S., Larsen, C. P., D’Agati, V. D., Nasr, S. H., & Santoriello, D. (2023). Clinicopathologic Spectrum of Lysozyme-Associated Nephropathy. Kidney International Reports, 8(8), 1585–1595. https://doi.org/10.1016/j.ekir.2023.05.007

De, A., Williams, S., Yao, Y., Jin, Z., Brittenham, G. M., Kattan, M., Lovinsky-Desir, S., & Lee, M. T. (2023). Acute chest syndrome, airway inflammation and lung function in sickle cell disease. PLOS ONE, 18(3), e0283349. https://doi.org/10.1371/journal.pone.0283349

Reeves, S. L., Peng, H. K., Wing, J. J., Cogan, L. W., Goel, A., Anders, D., Green, N. S., Lisabeth, L. D., & Dombkowski, K. J. (2023). Changes in Hydroxyurea Use Among Youths Enrolled in Medicaid With Sickle Cell Anemia After 2014 Revision of Clinical Guidelines. JAMA Network Open, 6(3), e234584. https://doi.org/10.1001/jamanetworkopen.2023.4584

Stenger, E., Xiang, Y., Wetzel, M., Gillespie, S., Chellapandian, D., Shah, R., Arnold, S. D., Bhatia, M., Chaudhury, S., Eckrich, M. J., Kanter, J., Kasow, K. A., Krajewski, J., Nickel, R. S., Ngwube, A. I., Olson, T. S., Rangarajan, H. G., Wobma, H., Guilcher, G. M. T., … Abraham, A. (2023). Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance. Transplantation and Cellular Therapy, 29(1), 47.e1-47.e10. https://doi.org/10.1016/j.jtct.2022.10.012

Green, N. S., Zapfel, A., Nnodu, O. E., Franklin, P., Tubman, V. N., Chirande, L., Kiyaga, C., Chunda-Liyoka, C., Awuonda, B., Ohene-Frempong, K., Inusa, B. P. D., Ware, R. E., Odame, I., Ambrose, E. E., Dogara, L. G., Oron, A. P., Willett, C., Thompson, A. A., Berliner, N., … Novelli, E. M. (2022). The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology. Blood Advances, 6(24), 6187–6197. https://doi.org/10.1182/bloodadvances.2022007698

Meacham, L. R., Pecker, L. H., Gee, B., & Mishkin, A. (2022). Incorporating gonadal health counseling into pediatric care of sickle cell patients. Hematology, 2022(1), 442–449. https://doi.org/10.1182/hematology.2022000382

Moore, A., Busch, M. P., Dziewulska, K., Francis, R. O., Hod, E. A., Zimring, J. C., D’Alessandro, A., & Page, G. P. (2022). Genome-wide metabolite quantitative trait loci analysis (mQTL) in red blood cells from volunteer blood donors. Journal of Biological Chemistry, 298(12), 102706. https://doi.org/10.1016/j.jbc.2022.102706

Smaldone, A., Manwani, D., Aygun, B., Appiah-Kubi, A., Smith-Whitley, K., & Green, N. S. (2022). Assessing Multi-Level Barriers to Medication Adherence in Youth with Sickle Cell Disease Using Pharmacy-Based Prescription Refill Data. Blood, 140(Supplement 1), 2149–2150. https://doi.org/10.1182/blood-2022-157527

Walters, M. C., Thompson, A. A., Kwiatkowski, J. L., Parikh, S., Mapara, M. Y., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Miller, A., Zhang, L., Chawla, A., Macari, E. R., Pierciey, F. J., Tisdale, J. F., & Kanter, J. (2022). Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study. Blood, 140(Supplement 1), 26–28. https://doi.org/10.1182/blood-2022-162288

Zhang, C., Tremblay, D., Magnotti, J., Ronner, L., Podoltsev, N. A., Gotlib, J., Heaney, M. L., Kuykendall, A., O’Connell, C. L., Fleischman, A. G., Mesa, R., Yacoub, A., Mascarenhas, J., & Shammo, J. M. (2022). Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis. Blood, 140(Supplement 1), 9693–9695. https://doi.org/10.1182/blood-2022-157873

Platzbecker, U., Komrokji, R. S., Fenaux, P., Zeidan, A. M., Sekeres, M. A., Savona, M. R., Madanat, Y. F., Santini, V., Van Eygen, K., Raza, A., Germing, U., Berry, T., Dougherty, S., Shah, S., Sun, L., Huang, F., Feller, F., Wan, Y., Ikin, A., & Sherman, L. (2022). Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study. Blood, 140(Supplement 1), 1106–1108. https://doi.org/10.1182/blood-2022-169050

Locatelli, F., Lang, P., Li, A., Corbacioglu, S., de la Fuente, J., Wall, D. A., Liem, R., Meisel, R., Mapara, M. Y., Shah, A. J., Cappellini, M. D. D., Kattamis, A., Sheth, S., Bobruff, Y., Bower, L., Zhang, L., Sharma, A., Song, Y., Hobbs, W., & Frangoul, H. (2022). Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. Blood, 140(Supplement 1), 4899–4901. https://doi.org/10.1182/blood-2022-166881

George, S. A., Veludhandi, A., Xiang, Y., Stenger, E., Arnold, S. D., Mehta, A., Schirmer, D. A., Spencer, J. B., Guilcher, G. M., Bhatia, M., Abraham, A., Gomez-Lobo, V., Krishnamurti, L., & Meacham, L. R. (2022). Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study. Blood, 140(Supplement 1), 1391–1392. https://doi.org/10.1182/blood-2022-168060

Frangoul, H., Locatelli, F., Bhatia, M., Mapara, M. Y., Molinari, L., Sharma, A., Lobitz, S., de Montalembert, M., Rondelli, D., Steinberg, M., Walters, M. C., Imren, S., Zhang, L., Sharma, A., Song, Y., Simard, C., Hobbs, W., & Grupp, S. (2022). Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease. Blood, 140(Supplement 1), 29–31. https://doi.org/10.1182/blood-2022-162353

Mishkin, A. D., Cheung, S. G., Hoffman, A., Leimbach, E. J., Dosovitz, S., & Mapara, M. (2022). High incidence of suicidal ideation in a series of patients with sickle cell disease after hematopoietic stem cell transplantation. Blood Advances, 6(19), 5542–5545. https://doi.org/10.1182/bloodadvances.2021006752

P., B., R., I., R., O., D., M., E., M., P., K., N., G., & A., B. (2022). O-08: NEUROCOGNITIVE IMPAIRMENT IN UGANDAN CHILDREN WITH SICKLE CELL ANEMIA COMPARED TO NON-SICKLE SIBLINGS. HemaSphere, 6, 05–06. https://doi.org/10.1097/01.hs9.0000872840.49305.3f

Kanter, J., Walters, M. C., Krishnamurti, L., Mapara, M. Y., Kwiatkowski, J. L., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Pierciey, F. J., Bonner, M., Miller, A., Zhang, X., Lynch, J., Kim, D., Ribeil, J.-A., Asmal, M., Goyal, S., Thompson, A. A., & Tisdale, J. F. (2022). Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. New England Journal of Medicine, 386(7), 617–628. https://doi.org/10.1056/nejmoa2117175

Roubinian, N. H., Reese, S. E., Qiao, H., Plimier, C., Fang, F., Page, G. P., Cable, R. G., Custer, B., Gladwin, M. T., Goel, R., Harris, B., Hendrickson, J. E., Kanias, T., Kleinman, S., Mast, A. E., Sloan, S. R., Spencer, B. R., Spitalnik, S. L., Busch, M. P., & Hod, E. A. (2022). Donor genetic and nongenetic factors affecting red blood cell transfusion effectiveness. JCI Insight, 7(1). https://doi.org/10.1172/jci.insight.152598

Akpan, I. J., & Pavord, S. (2022). Gynecologic Conditions and Anemia: What Can We Do About Iron Deficiency Anemia in Women? The Hematologist, 19(3). https://doi.org/10.1182/hem.v19.3.2022311

Dei Zotti, F., Qiu, A., La Carpia, F., Moriconi, C., & Hudson, K. E. (2021). A New Murine Model of Primary Autoimmune Hemolytic Anemia (AIHA). Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.752330

Tremblay, D., Srisuwananukorn, A., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A. T., O’Connell, C. L., Shammo, J. M., Fleischman, A., Mesa, R. A., Yacoub, A., Hoffman, R., Moshier, E., Zubizarreta, N., & Mascarenhas, J. (2021). European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database. Blood, 138(Supplement 1), 240–240. https://doi.org/10.1182/blood-2021-148020

Arnold, S. D., Bakshi, N., Chang, Z., Ross, D., Abraham, A., Bhatia, M., Guilcher, G. M. T., Haight, A., Hsieh, M., Kasow, K. A., Lane, P. A., Meacham, L., Olowoselu, F. O., & Krishnamurti, L. (2021). Long-Term Quality of Life after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from the Sickle Cell Transplant Evaluation of Long Term and Late Effects Registry (STELLAR). Blood, 138(Supplement 1), 425–425. https://doi.org/10.1182/blood-2021-154280

Askew, M., Smaldone, A., Gold, M. A., Smith-Whitley, K., Strouse, J. J., Jin, Z., & Green, N. S. (2021). National Survey of Pediatric Sickle Cell Providers on Their Contraceptive Practices for Female Patients. Blood, 138(Supplement 1), 1898–1898. https://doi.org/10.1182/blood-2021-154083

Srisuwananukorn, A., Percha, B., Abu-Zeinah, G., Scandura, J., Krichevsky, S., Taylor, E., Silver, R. T., Thibaud, S., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A. T., O’Connell, C., Shammo, J. M., Fleischman, A., Mesa, R. A., Yacoub, A., Hoffman, R., … Tremblay, D. (2021). Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics. Blood, 138(Supplement 1), 2583–2583. https://doi.org/10.1182/blood-2021-150561

Veludhandi, A., John, T. D., Bakshi, N., Arnold, S. D., Bhatia, M., Lane, P. A., Meacham, L., Khemani, K., Chaudhury, S., Olowoselu, F. O., Kasow, K. A., Hsieh, M., Abraham, A., Guilcher, G. M. T., & Krishnamurti, L. (2021). Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLaR). Blood, 138(Supplement 1), 3030–3030. https://doi.org/10.1182/blood-2021-152383

Santini, V., Fenaux, P., Van Eygen, K., Raza, A., Germing, U., Font, P., Diez-Campelo, M., Thepot, S., Vellenga, E., Patnaik, M. M., Jang, J. H., Sherman, L., Berry, T., Feller, F., Dougherty, S., Sun, L., Wan, Y., Rizo, A., Huang, F., & Platzbecker, U. (2021). On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood, 138(Supplement 1), 2598–2598. https://doi.org/10.1182/blood-2021-148876

Tisdale, J. F., Thompson, A. A., Mapara, M. Y., Kwiatkowski, J. L., Krishnamurti, L., Aygun, B., Kasow, K. A., Rifkin-Zenenberg, S., Schmidt, M., Pierciey, F. J., Whitney, D., Rogers, C., Nnamani, M., Foos, M., Miller, A., Zhang, X., Lynch, J., Walters, M. C., Kanter, J., & Bonner, M. (2021). Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT). Blood, 138(Supplement 1), 561–561. https://doi.org/10.1182/blood-2021-147760

Walters, M. C., Tisdale, J. F., Mapara, M. Y., Krishnamurti, L., Kwiatkowski, J. L., Aygun, B., Kasow, K. A., Rifkin-Zenenberg, S., Jaroscak, J., Garbinsky, D., Chirila, C., Gallagher, M. E., Zhang, X., Ho, P.-R., Thompson, A. A., & Kanter, J. (2021). Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood, 138(Supplement 1), 7–7. https://doi.org/10.1182/blood-2021-146905